US 7,547,441 B2
	PAI-2 conjugates for the treatment and imaging of cancer
Marie Ranson, Austinmer (Australia); Barry John Allen, Yowie Bay (Australia); and Clive Leighton Bunn, West Ryde (Australia)
Assigned to PAI-2 Pty Limited, Thornleigh (Australia); University of Wollongong, Gwynneville (Australia); and Medical Scitec Australia Pty Ltd, Yowie Bay (Australia)
Filed on Feb. 23, 2001, as Appl. No. 9/790,900.
Claims priority of application No. PQ5824 (AU), filed on Feb. 24, 2000.
Prior Publication US 2002/0002134 A1, Jan. 03, 2002
Int. Cl. A61K 39/385 (2006.01); A61K 35/58 (2006.01); C12Q 1/26 (2006.01); C12N 5/06 (2006.01); C12N 5/00 (2006.01); G01N 23/00 (2006.01); G01N 33/48 (2006.01)

U.S. Cl. 424—194.1  [424/193.1; 424/196.11; 424/197.11; 424/542; 435/26; 435/326; 435/346; 436/57; 436/64; 436/86; 436/164; 436/166; 436/172; 514/1; 514/2; 514/4]

17 Claims

1. A PAI-2 conjugate molecule that is internalized by a cell that expresses a uPA/uPAR complex, said molecule comprising a component (i) that is PAI-2 and, bound or linked via a chelator thereto, a component (ii) that is a radioisotope, wherein component (i) binds to uPA.